Zobrazeno 1 - 10
of 492
pro vyhledávání: '"C, Schwentner"'
Autor:
S, Hintermeier, C, Schwentner
Publikováno v:
Urologie (Heidelberg, Germany). 61(12)
Autor:
S. Hintermeier, C. Schwentner
Publikováno v:
Die Urologie. 61:1390-1391
Publikováno v:
Indian Journal of Urology, Vol 24, Iss 3, Pp 309-312 (2008)
During the 10 th week of gestation human prostate development is about to start. Androgens are the crucial factors to stimulate the initial interactions between the epithelium and mesenchyme. One of the key events in androgen metabolism is the transf
Externí odkaz:
https://doaj.org/article/fe85884cd7a940809392bc9d3b2fa3f3
Autor:
C, Wülfing, M, Bögemann, P J, Goebell, P, Hammerer, S, Machtens, D, Pfister, C, Schwentner, T, Steuber, G, von Amsberg, M, Schostak
Publikováno v:
Der Urologe. Ausg. A. 58(9)
There is an ongoing change of paradigm in the treatment of metastatic prostate cancer (mPC). Taxan-based chemotherapy demonstrated a prolonged survival of patients in several randomized phase III trials. This is true in the situation of metastatic ca
Autor:
M, Schostak, F, König, M, Bögemann, P, Goebell, P, Hammerer, S, Machtens, C, Schwentner, C, Thomas, G, von Amsberg, F-C, von Rundstedt, A, Heidenreich
Publikováno v:
Der Urologe. Ausg. A. 57(7)
In March 2017 the 'Advanced Prostate Cancer Consensus Conference' (APCCC) took place in St. Gallen (Switzerland). The APCCC-panelists are internationally well known experts. With the actual data in mind they discussed treatment options for patients w
Publikováno v:
Der Urologe. Ausg. A. 57(6)
Modifications in resection techniques may overcome obvious limitations of conventionally performed transurethral resection (e. g., tumor fragmentation) of bladder tumors or provide an easier patient treatment algorithm (e. g., tumor vaporization).The
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
K, Miller, P, Albers, R, Eichenauer, G, Geiges, M-O, Grimm, F, König, G, Mickisch, D, Pfister, C, Schwentner, H, Suttmann, S, Zastrow
Publikováno v:
Der Urologe. Ausg. A. 55(9)
Therapies currently available in Germany for metastatic castration-resistant prostate cancer (mCRPC) include docetaxel, cabazitaxel, abiraterone acetate, enzalutamide and radium-223, all of which offer a potential survival benefit that adds up in the
Publikováno v:
Der Urologe. Ausg. A. 54(4)
Nonmuscle-invasive bladder cancer (NMIBC) comprises a very heterogeneous group of malignancies; the biological behavior of these tumors depends primarily on their grading. Low-grade NMIBC are characterized by a high propensity for recurrence but a ve
Publikováno v:
Der Urologe. 45:229-234